Bayer Looks To Singapore To Develop Cancer Drugs For Asian Patients
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Bayer Schering Pharma Asia Pacific, a unit of Germany-based Bayer Schering Pharma AG, and the Yong Loo Lin School of Medicine of the National University of Singapore will team up to develop novel cancer-fighting drugs targeted specifically at Asian patients